Study | Sample Size (n) | Re-Scan Timing | Mean Primary Tumor Volume Reduction (Range) by Fraction (Fx) 10 | Mean Primary Tumor Volume Reduction (Range) by Fx 20 | Mean Primary Tumor Volume Reduction (Range) by End of Treatment |
---|---|---|---|---|---|
Bhide IJROBP 2010 [8] | 20 (10 OPC, 6 Laryng or Hypoph, 4 NPC) | Weeks 2, 3, 4, 5 | 3.2% CTV1, where CTV1 was gross disease + 1.5 cm margin (0.74–5.6%) | – | – |
Liu IJROBP 2018 [9] | 18 (16 OPC, 1 NPC, 1 UP) | Fx 10 and 22 | 16.4% GTV, 15.4% CTV1 where CTV1 was GTV + 0.5 cm margin (GTV − 2.1 to 37.1%, CTV1 0.7 to 30.5%) | – | 32.6% GTV, 28.2% CTV1 by fraction 22 (GTV 9.8 to 56.3%, CTV1 12.0 to 44.8%) |
Capelle Clin Oncol 2012 [10] | 20 (17 HNSCC, 3 NPC) | Fx 15 | – | 28.8% GTV, 16% PTV60/66 where PTV60 was a 0.5 cm expansion on CTV60 (involved postop regions) for adjuvant patients and PTV66 was a 0.5 cm expansion on the GTV for definitive patients (GTV 1.6 to 60%, PTV 0 to 45%) | – |
Chitapanarux J Radiat Res 2015 [11] | 17 (17 NPC) | Fx 17 | – | 18.4% GTV, − 7.4% CTV70 by fraction 17 where CTV70 was GTV + 0.5 cm margin (range NS) | – |
Dewan Asian Pac J 2016 [12] | 30 (15 OPC, 10 OC, 5 Hypoph) | Fx 20 | – | 47.62% GTV, 43.76% CTV where CTV was GTV + 0.5–2 cm margin, 49.69% PTV where PTV was 0.2–0.5 cm margin by fraction 20 (range NS) | – |
Lee Cancer Res Treat 2016 (13) | 159 (159 NPC) | Fx 15 | – | 43.4% GTV (− 3.8 to 93.5%) | – |
Lu Chin Med J 2012 [14] | 43 (43 NPC) | Fx 20 | – | 30.1% GTV by Fraction 20 (0.6 to 77.2%) | – |
Mahmoud Technol Cancer Res Treat 2017 [15] | 22 (11 OPC, 7 OC, 2 Laryng, 1 Hypoph, 1 NPC) | Fx 15, 27 | – | 7.2% CTV-HR for definitive (− 3 to 18%) 7.8% CTV-HR for postoperative (0 to 18%) where CTV-HR “included the regions and/or subjacent lymph node chains within 2 to 3 cm of gross disease” | 12.8% CTV-HR for definitive (−7 to 29%) 10.9% CTV-HR for postoperative (3 to 20%) |
Surucu Technol Cancer Res Treat 2016 [16] | 48 (28 OPC, 7 NPC, 5 Hypoph, 8 OC) | Week 4 (median; rescans done at a median dose of 37.8Gy with range of 14.4–51.5 Gy) | – | 26.8% GTV (range NS) | – |
Surucu Technol Cancer Res Treat 2017 [27] | 34 (20 OPC, 6 OC, 5 NPC, 3 Hypoph) | Week 4 (median; rescans done at a median dose of 37.8Gy with range of 27.0–48.6 Gy) | – | – | 35.2% GTV (−18.8 to 79.6%) |
Castelli Radiat Oncol 2015 [3] | 15 (11 OPC, 2 OC, 1 Laryng, 1 Hypoph) | Weekly | – | – | 31% CTV70 where CTV70 was GTV + 0.5 cm margin (−13 to 73%) |
Loo Clin Oncol 2011 [17] | 5 (3 OPC, 1 OC, 1 Laryng) | Weekly | – | – | 5.8% CTV68 where CTV68 “encompassed the GTV and high-risk regions” (range NS) |
Beltran J Appl Clin Med 2012 [18] | 16 (7 OPC, 5 OC, 1 Hypoph, 1 NPC, 2 NS) | Fx 15, 25 | – | – | 13.25% PTV2 where PTV2 was the CTV2 (GTV + high-risk regions) + 0.5 cm margin (range NS) |
Fung Med Dosim 2012 [19] | 10 (10 NPC) | Fx 21, 31 approx. | – | – | 53.95% CTV, 36.19% PTV where PTV was the CTV + 0.3 cm (range NS) |
Jin Radiat Oncol 2013 [20] | 9 (9 NPC) | Fx 23 | – | – | 9.4% GTV by fraction 23 (range NS) (non-sig reduction) |
Schwartz Radiother Oncol 2013 [21] | 22 (22 OPC) | Daily scans, Weekly recalc | – | 5% CTV where CTV was the GTV + high-risk regions (−21 to 13%) | 8% CTV (−6 to 19%) |
Tan Onco Targets Ther 2013 [22] | 20 (20 NPC) | Weekly | – | – | 55.3% GTV (range NS) |
Fung J Radiat Res 2014 [23] | 30 (30 NPC) | Every 2 Fx | – | – | 35.7% GTV (range NS) |
Huang Radiat Oncol 2015 [24] | 19 (19 NPC) | Every 5 Fx | – | – | 65.6% GTV (range NS) |
Kataria Br J Radiol [25] | 36 (21 OPC, 5 Laryng, 10 Hypoph) | Fx 23 | – | – | 34.0% GTV (range NS) |
Zhang Radiother Oncol 2016 [26] | 13 (13 OPC) | Weekly | – | – | 24.43% CTV70 where CTV70 was GTV + 0.5 cm margin (−12.6 to 62.1%) |
Range of median tumor volume (GTV / CTV / PTV) reductions of the included studies | 3 to 16% | 7 to 48% | 6 to 66% |